Hepatitis C Virus Infection, Response to Therapy of
15
1
1
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 15 trials
100.0%
+13.5% vs benchmark
27%
4 trials in Phase 3/4
29%
2 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (15)
Rapid HCV Treatment Access for Persons Who Use Drugs
Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor
Possible Differences in HCC Course Depending on DAA Treatment
Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures
HCV Reinfection After DAA Therapy in PWID in Belgium
HCV Reinfection in in HIV/HCV-coinfected Patients Achieving SVR by Antiviral Therapy
HCV Reinfection in HD Patients Achieving SVR
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
CHAMPS Study: Chronic HepAtitis C Management to ImProve OutcomeS
Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus
Safety & Efficacy of Sofosbuvir 400mg/Ledipasvir 90mg in the Treatment of Chronic Hepatitis C Adolescents
Safety and Efficacy of Generic Sofosbuvir and Ribavirin for Treatment-naive Genotype 2 Chronic Hepatitis C
Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients
Effects of Activity and Education Program on Patients With Chronic Hepatitis C Infection
Study to Assess Safety,Tolerability,Pharmacokinetics & Antiviral Activity of JTK-853 in Hepatitis C Virus Genotype 1 Infected Subjects